Epizyme (EPZM) Tops Q2 EPS by 10c

Epizyme (NASDAQ: EPZM) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• UBS Downgrades FANUC Corp (6954:JP) (FANUY) to Neutral
• Kepler Cheuvreux Downgrades Carl Zeiss Meditec AG (AFXG:GR) (CZMWY) to Reduce